Werewolf Therapeutics Inc
Research Werewolf Therapeutics Inc (HOWL) on Bullrun: market cap USD 43.25M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHOWL
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 43.25M
- Financial periodQ2 2026
- RevenueUSD 21.00M
- Net incomeUSD 3.67M
- Free cash flowUSD 6.63M
Valuation Snapshot
latest market cap is USD 43.25M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 60.82M | -USD 60.29M | n/a | -1.33 | USD 57.05M | USD 32.09M | USD 24.81M |
| FY2024 | USD 1.89M | -USD 70.52M | -USD 56.44M | n/a | -1.63 | USD 111.00M | USD 32.09M | USD 73.39M |
| FY2023 | n/a | -USD 37.37M | -USD 33.38M | n/a | -1.05 | USD 134.34M | USD 40.00M | USD 111.37M |
| FY2022 | n/a | -USD 53.81M | -USD 44.21M | n/a | -1.86 | USD 129.32M | USD 15.55M | USD 122.34M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 43.25M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 30.62M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 66.34M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 139.70M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 63.03M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 325.30M | n/a | n/a | n/a |
About Werewolf Therapeutics Inc
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Werewolf Therapeutics Inc's market cap?
Werewolf Therapeutics Inc's market capitalization is USD 43.25M.
What does Werewolf Therapeutics Inc do?
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.